Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$4.74 +0.4%	$8.48	$3.80 ▼ $47.80	$7.29M	-1.27	140,931 shs	32,494 shs
GLMD Galmed Pharmaceuticals	$1.45 -1.0%	$1.77	$1.15 ▼ $23.80	$2.38M	0.58	1.10 million shs	56,054 shs
IMCC IM Cannabis	$2.62 +2.1%	$2.84	$1.29 ▼ $7.12	$10.61M	2.2	118,447 shs	17,842 shs
RNAZ TransCode Therapeutics	$11.26 -2.8%	$9.17	$6.15 ▼ $739.20	$9.39M	1.46	201,104 shs	13,620 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	+6.55%	-6.53%	-48.25%	-36.75%	-87.58%
GLMD Galmed Pharmaceuticals	+2.82%	+0.69%	-30.14%	+15.87%	-57.81%
IMCC IM Cannabis	-1.15%	+2.39%	-22.82%	+58.15%	-6.88%
RNAZ TransCode Therapeutics	+0.70%	+4.32%	+27.22%	+51.50%	-99.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	2.7923 of 5 stars	3.5	5.0	2.0	1.7	0.0
GLMD Galmed Pharmaceuticals	0.828 of 5 stars	0.0	2.0	2.4	2.5	0.6
IMCC IM Cannabis	1.0114 of 5 stars	0.0	5.0	3.7	0.0	0.0
RNAZ TransCode Therapeutics	2.3438 of 5 stars	3.5	2.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$31.00	554.01% Upside
GLMD Galmed Pharmaceuticals	2.00	Hold	N/A	N/A
IMCC IM Cannabis	0.00	N/A	N/A	N/A
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	2,386.68% Upside

Current Analyst Ratings Breakdown

Latest GLMD, IMCC, RNAZ, and ACXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/12/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$31.00
5/15/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$160.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.25 per share	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$9.87 per share	N/A
IMCC IM Cannabis	$54.47M	0.19	N/A	N/A	$1.03 per share	2.55
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	($54.96) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$10.69	N/A	N/A	N/A	N/A	-436.83%	-192.25%	N/A
GLMD Galmed Pharmaceuticals	-$7.52M	-$16.66	N/A	∞	N/A	N/A	-32.21%	-28.59%	8/27/2025 (Estimated)
IMCC IM Cannabis	-$7.72M	-$0.54	N/A	N/A	N/A	-4.19%	-62.20%	-5.10%	N/A
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-578.88%	-222.61%	N/A

Latest GLMD, IMCC, RNAZ, and ACXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	IMCC IM Cannabis	-$0.1367	-$0.0653	+$0.0714	-$0.07	$12.88 million	$9.21 million
8/11/2025	Q2 2025	ACXP Acurx Pharmaceuticals	-$2.00	-$1.89	+$0.11	-$1.89	N/A	N/A
5/22/2025	Q1 2025	GLMD Galmed Pharmaceuticals	N/A	-$0.62	N/A	-$0.62	N/A	N/A
5/21/2025	Q4 2024	RNAZ TransCode Therapeutics	-$2.00	-$0.60	+$1.40	-$2.51	$0.30 million	N/A
5/15/2025	Q1 2025	IMCC IM Cannabis	-$0.2540	$0.06	+$0.3140	$0.06	$11.45 million	$8.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	2.38	1.93
GLMD Galmed Pharmaceuticals	N/A	9.02	9.02
IMCC IM Cannabis	0.10	0.72	0.59
RNAZ TransCode Therapeutics	N/A	5.20	5.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
GLMD Galmed Pharmaceuticals	76.14%
IMCC IM Cannabis	7.68%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	20.30%
GLMD Galmed Pharmaceuticals	19.80%
IMCC IM Cannabis	5.91%
RNAZ TransCode Therapeutics	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	1.54 million	1.23 million	Optionable
GLMD Galmed Pharmaceuticals	20	1.65 million	1.33 million	Not Optionable
IMCC IM Cannabis	340	4.05 million	3.81 million	Not Optionable
RNAZ TransCode Therapeutics	9	834,000	834,000	Not Optionable

GLMD, IMCC, RNAZ, and ACXP Headlines

Recent News About These Companies

Transcode Therapeutics Inc News (RNAZ) - Investing.com

July 4, 2025 | investing.com

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025 | prnewswire.com

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 6, 2025 | finanznachrichten.de

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025 | prnewswire.com

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules

May 4, 2025 | investing.com

TransCode reports progress in metastatic cancer trial

May 3, 2025 | uk.investing.com

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025 | prnewswire.com

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

May 2, 2025 | finance.yahoo.com

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

May 2, 2025 | financial-news.co.uk

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025 | prnewswire.com

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

April 21, 2025 | prnewswire.com

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy

April 18, 2025 | zacks.com

Transcode Therapeutics price target lowered to $10 from $20 at H.C. Wainwright

April 17, 2025 | markets.businessinsider.com

Transcode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trial

March 28, 2025 | markets.businessinsider.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

March 28, 2025 | finanznachrichten.de

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

March 27, 2025 | prnewswire.com

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

March 25, 2025 | prnewswire.com

Transcode to sell 10.25M shares at 98c per share in registered direct offering

March 25, 2025 | markets.businessinsider.com

TransCode Therapeutics stock slides after announces to raise $10M securities offering

March 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD, IMCC, RNAZ, and ACXP Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$4.74 +0.02 (+0.42%)

As of 03:01 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Galmed Pharmaceuticals NASDAQ:GLMD

$1.44 -0.02 (-1.03%)

As of 03:00 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

IM Cannabis NASDAQ:IMCC

$2.62 +0.05 (+2.10%)

As of 02:56 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

TransCode Therapeutics NASDAQ:RNAZ

$11.26 -0.33 (-2.85%)

As of 03:03 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time